You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君实生物(01877.HK)双抗体疗法III期临床试验达主要研究终点
阿思达克 01-27 05:03
君实生物(01877.HK)公布,etesevimab 2,800 mg及bamlanivimab2,800 mg双抗体疗法显着降低了近期被确诊为新型冠状病毒肺炎高重症化风险患者相关住院和死亡事件,达到了BLAZE-1研究III期临床试验的主要研究终点。

在III期试验中,etesevimab及bamlanivimab双抗体疗法的安全性特徵与评估该等抗体的其他I期、II期及III期试验观察结果一致。

试验结果显示,etesevimab在预防及治疗新冠病毒感染方面均具有良好疗效。公司与中科院微生物所共同开发该新冠病毒中和抗体後,礼来制药从公司引进etesevimab。其中,公司主导大中华地区的开发活动。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account